A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine for 3rd Line Treatment of Patients With Metastatic Pancreatic Cancer.

Trial Profile

A Ph Ib Study of Fractionated 90Y-hPAM4 Plus Gemcitabine for 3rd Line Treatment of Patients With Metastatic Pancreatic Cancer.

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Feb 2017

At a glance

  • Drugs Y-90 clivatuzumab tetraxetan (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions
  • Sponsors Immunomedics
  • Most Recent Events

    • 19 Aug 2015 According to an Immunomedics media release, final results from this trial were published online in the European Journal of Cancer.
    • 15 Feb 2015 Planned End Date changed from 1 Mar 2015 to 1 Sep 2015 as reported by ClinicalTrials.gov.
    • 15 Feb 2015 Planned primary completion date changed from 1 Jun 2014 to 1 Jun 2015 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top